316 related articles for article (PubMed ID: 12381304)
1. Molecular mechanism of the interaction between MDM2 and p53.
Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR
J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304
[TBL] [Abstract][Full Text] [Related]
2. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes.
Schon O; Friedler A; Freund S; Fersht AR
J Mol Biol; 2004 Feb; 336(1):197-202. PubMed ID: 14741215
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
4. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
[TBL] [Abstract][Full Text] [Related]
5. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.
Liu Z; Olejniczak ET; Fesik SW
Protein Expr Purif; 2004 Oct; 37(2):493-8. PubMed ID: 15358376
[TBL] [Abstract][Full Text] [Related]
6. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
[TBL] [Abstract][Full Text] [Related]
7. Sequence-specific 1H, 15N, and 13C assignment of the N-terminal domain of the human oncoprotein MDM2 that binds to p53.
Stoll R; Renner C; Mühlhahn P; Hansen S; Schumacher R; Hesse F; Kaluza B; Engh RA; Voelter W; Holak TA
J Biomol NMR; 2000 May; 17(1):91-2. PubMed ID: 10909873
[No Abstract] [Full Text] [Related]
8. Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2.
Yadahalli S; Neira JL; Johnson CM; Tan YS; Rowling PJE; Chattopadhyay A; Verma CS; Itzhaki LS
Sci Rep; 2019 Jan; 9(1):693. PubMed ID: 30679555
[TBL] [Abstract][Full Text] [Related]
9. Autoinhibition of MDMX by intramolecular p53 mimicry.
Chen L; Borcherds W; Wu S; Becker A; Schonbrunn E; Daughdrill GW; Chen J
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4624-9. PubMed ID: 25825738
[TBL] [Abstract][Full Text] [Related]
10. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
Uhrinova S; Uhrin D; Powers H; Watt K; Zheleva D; Fischer P; McInnes C; Barlow PN
J Mol Biol; 2005 Jul; 350(3):587-98. PubMed ID: 15953616
[TBL] [Abstract][Full Text] [Related]
11. Phage-peptide display identifies the interferon-responsive, death-activated protein kinase family as a novel modifier of MDM2 and p21WAF1.
Burch LR; Scott M; Pohler E; Meek D; Hupp T
J Mol Biol; 2004 Mar; 337(1):115-28. PubMed ID: 15001356
[TBL] [Abstract][Full Text] [Related]
12. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
Zondlo SC; Lee AE; Zondlo NJ
Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
[TBL] [Abstract][Full Text] [Related]
13. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of how stress-induced MDMX phosphorylation activates p53.
Chen X; Gohain N; Zhan C; Lu WY; Pazgier M; Lu W
Oncogene; 2016 Apr; 35(15):1919-25. PubMed ID: 26148237
[TBL] [Abstract][Full Text] [Related]
16. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
Popowicz GM; Czarna A; Holak TA
Cell Cycle; 2008 Aug; 7(15):2441-3. PubMed ID: 18677113
[TBL] [Abstract][Full Text] [Related]
17. Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation.
McCoy MA; Gesell JJ; Senior MM; Wyss DF
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1645-8. PubMed ID: 12552135
[TBL] [Abstract][Full Text] [Related]
18. Design of a novel MDM2 binding peptide based on the p53 family.
Madhumalar A; Lee HJ; Brown CJ; Lane D; Verma C
Cell Cycle; 2009 Sep; 8(17):2828-36. PubMed ID: 19713735
[TBL] [Abstract][Full Text] [Related]
19. p53 Phosphomimetics Preserve Transient Secondary Structure but Reduce Binding to Mdm2 and MdmX.
Levy R; Gregory E; Borcherds W; Daughdrill G
Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30832340
[TBL] [Abstract][Full Text] [Related]
20. QSAR: hydropathic analysis of inhibitors of the p53-mdm2 interaction.
Galatin PS; Abraham DJ
Proteins; 2001 Nov; 45(3):169-75. PubMed ID: 11599019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
